The pharmacologic and pathophysiologic rationale for using NSAIDs in ocular inflammatory disease and ocular surgery

International Ophthalmology Clinics

Volumn 46, Issue 4, 2006, Pages 7-11

  Lindstrom, Richard ^a  

^a Minnesota Eye Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMFENAC; DICLOFENAC; FLURBIPROFEN; INDOMETACIN; KETOROLAC TROMETAMOL; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; CATARACT EXTRACTION; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; EYE INFLAMMATION; EYE SURGERY; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MYDRIASIS; NONHUMAN; PATHOPHYSIOLOGY; PHOTOPHOBIA; POSTOPERATIVE INFLAMMATION; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; REVIEW; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ENDOPHTHALMITIS; HUMANS; INTRAOPERATIVE PERIOD; OPHTHALMIC SOLUTIONS; OPHTHALMOLOGIC SURGICAL PROCEDURES; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 33750369952     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iio.0000212131.98760.a9     Document Type: Review

References (12)

1. O'Brien TP. Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Res Med Opin. 2005;21:1131-1137.
2. Lane SS, Modi SS, Holland EJ, et al. Nepafenac ophthalmic suspension 0.1% before and after surgery for postoperative anterior segment inflammation. Paper presented at the American Society of Cataract and Refractive Surgery annual meeting, April 14, 2005, Washington, DC.
3. Stewart WC, Stewart R, Maxwell WA, et al. Preoperative and postoperative clinical evaluation of nepafenac 0.1% ophthalmic suspension for postcataract inflammation. Paper presented at the American Society of Cataract and Refractive Surgery, April 18, 2005, Washington, DC.
4. Solomon KD, Cheetham JK, DeGryse R, et al. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology. 2001;108:331-337.
5. Heier J, Cheetham JK, Degryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. Am J Ophthalmol. 1999;127:253-259.
6. Flach AJ, Stegman RC, Graham J, et al. Prophylaxis of aphakic cystoid macular edema without corticosteroids. A paired-comparison, placebo-controlled double-masked study. Ophthalmology. 1990;97:1253-1258.
7. Flach AJ, Jampol LM, Weinberg D, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol. 1991;112:514-519.
8. Sivaprasad S, Bunce C, Wormald R. Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. Br J Ophthalmol. 2005;89:1420-1422.
9. McColgin AZ, Raizman MB. Efficacy of topical voltaren in reducing the incidence of postoperative cystoid macular edema. Invest Ophthalmol Vis Sci. 1999;40:ARVO Abstract 1529.
10. Rho DS. Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J Cataract Refract Surg. 2003;29:2378-2384.
11. Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation. 2003;27:281-291.
12. McColgin AZ, Heier JS. Control of intraocular inflammation associated with cataract surgery. Curr Opinion Ophthal. 2000;11:3-6.